Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q2 2025 · 10-Q
Revenue$3.58M$3.58M+31.1% vs Q2 2024 Net Income-$610.00K-$610.00KN/M vs Q2 2024 EPS Diluted-$0.59-$0.59N/M vs Q2 2024 Gross Profit$1,361,000+37.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived$354,000N/M Free Cash Flowderived$328,000N/M Margins · derivedGross margin38.0%+1.8 pt vs Q2 2024
Operating margin-23.7%+20.5 pt vs Q2 2024
Net margin-17.0%+37.3 pt vs Q2 2024
ended Sep 30, 2024 · filed Nov 7, 2024 · 38 d after period end